The United States Food and Drug Administration (USFDA) has conducted a current Good Manufacturing Practices (cGMP) inspection at Cipla’s Pithampur manufacturing facility from February 6 - 17, 2023. On conclusion of the inspection, the Company has received 8 inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
